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Abstract Mutations in ABCA1 uniformly decrease plasma
HDL-cholesterol (HDL-C) and reduce cholesterol efflux,
yet different mutations in ABCA1 result in different pheno-
typic effects in heterozygotes. For example, truncation mu-
tations result in significantly lower HDL-C and apoliprotein
A-I (apoA-I) levels in heterozygotes compared with nontrun-
cation mutations, suggesting that truncation mutations may
negatively affect the wild-type allele. To specifically test this
hypothesis, we examined ABCA1 protein expression in re-
sponse to 9-
 
cis
 
-retinoic acid (9-
 
cis
 
-RA) and 22-
 
R
 
-hydroxycho-
lesterol (22-
 
R
 
-OH-Chol) in a collection of human fibroblasts
representing eight different mutations and observed that
truncation mutations blunted the response to oxysterol
stimulation and dominantly suppressed induction of the re-
maining full-length allele to 5–10% of wild-type levels.
mRNA levels between truncation and nontruncation muta-
tions were comparable, suggesting that ABCA1 expression
was suppressed at the protein level. Dominant negative ac-
tivity of truncated ABCA1 was recapitulated in an in vitro
model using transfected Cos-7 cells. Our results suggest
that the severe reduction of HDL-C in patients with trunca-
tion mutations may be at least partly explained by dominant
negative suppression of expression and activity of the re-
maining full-length ABCA1 allele.  These data suggest that
ABCA1 requires a physical association with itself or other
molecules for normal function and has important pharma-
cogenetic implications for individuals with truncation muta-
tions.—
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Mutations in the ABCA1 gene have been identified as
the underlying cause of Tangier Disease (TD) and of a
dominantly inherited form of hypoalphalipoproteinemia
(FHA) associated with reduced cellular cholesterol efflux
(1–4). TD is a rare form of HDL cholesterol (HDL-C) de-
ficiency in which patients have mutations in both alleles of
ABCA1, resulting in greatly impaired cholesterol efflux
and virtually no circulating HDL-C (5). Intracellular cho-
lesterol accumulation in TD patients often results in clini-
cal manifestations of orange tonsils, hepatosplenomegaly,
and peripheral neuropathy (5).
Persons heterozygous for ABCA1 mutations have FHA,
a less-severe clinical outcome of deficient cholesterol ef-
flux (6). Generally, cells of FHA patients do not have ex-
cessive intracellular cholesterol ester accumulation, a fea-
ture attributed to the activity of the remaining wild-type
allele. Compared with unaffected family members, het-
erozygotes have HDL-C and apolipoprotein A-I (apoA-I)
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levels that are reduced by approximately 40% accompa-
nied by a mild decrease in apoA-II and decreased HDL-C
particle size (6, 7). In some instances, certain FHA fami-
lies have cholesterol efflux and HDL-C measurements
that are considerably less than 50% of wild-type levels,
raising the possibility that the function of the wild-type
gene product is negatively affected by particular muta-
tions (6). Understanding the molecular consequences of
ABCA1 mutations on protein function will provide crucial
information about the relationship between ABCA1 ex-
pression and HDL-C, which is a demonstrated protective
factor against the development of cardiovascular disease.
To this end, we investigated the effect of eight different
ABCA1 mutations on expression of ABCA1 mRNA and
protein in primary fibroblasts in individuals from FHA
and TD families (6). The mutations investigated in this
study are dispersed throughout the ABCA1 gene and were
specifically chosen to represent several different types, in-
cluding missense, small in-frame deletions, frameshift,
and nonsense mutations. ABCA1 expression is induced by
9-
 
cis
 
-retinoic acid (9-
 
cis
 
-RA) and 22-
 
R
 
-hydroxycholesterol
(22-
 
R
 
-OH-Chol), which signal the presence of excess cho-
lesterol (8–12). Here, we report that the normal upregula-
tion of full-length ABCA1protein in response to 9-
 
cis
 
-RA,
22-
 
R
 
-OH-Chol is dominantly suppressed when one ABCA1
allele is prematurely truncated, resulting in ABCA1 pro-
tein levels that are approximately 5–10% of those ob-
served in wild-type cells, despite comparable mRNA levels.
MATERIALS AND METHODS
 
Subjects
 
Subjects heterozygous for ABCA1 mutations from TD and
FHA kindreds have been described (6). One new heterozygous
subject is included in this study who is from a new TD kindred
( JP2) and contains the truncation mutation R1851X (13). All
subjects have informed consent for participation, and all re-
ceived ethical approval by the University of British Columbia (6).
 
Cell culture and transfection
 
RAW murine macrophages and human fibroblasts were main-
tained in DMEM (Canadian Life Technologies) with 10% fetal
calf serum (FCS), 50 U/ml penicillin-streptomycin, 2 mmol
 
l
 
-glutamine, 1
 

 
 nonessential amino acids (Canadian Life Tech-
nologies), and 10 ng/ml epidermal growth factor (Sigma). ABCA1
expression was stimulated by the replacement of the growth me-
dium with media containing delipidated serum (Sigma) with either
ethanol (control) or 10 
 

 
mol/l 9-
 
cis
 
 RA (10 mg/ml stock in eth-
anol, Sigma) and 4 
 

 
g/ml 22-
 
R
 
-OH-Chol (4 mg/ml stock in eth-
anol; Steraloids) for up to 24 h. Cos-7 cells were cultured in
DMEM with 10% FCS, 50 U/ml penicillin-streptomycin, and 2
mmol/l 
 
l
 
-glutamine. One day prior to transfection, cells were
seeded at 1.6 
 

 
 10
 
5
 
/well into 12-well plates coated with type I
collagen. The next day, cells at approximately 95% confluence
were transfected using Lipofectamine 2000 (Canadian Life Tech-
nologies) following the manufacturer’s recommendations. Cells
were transfected with wild-type or truncated human ABCA1
cDNA expression constructs tagged with the FLAG epitope
(DYKDDDDK) at the C terminus to permit verification of expres-
sion in transfected cells as described (13).
 
Protein isolation and Western blotting
 
Cell pellets were lysed by trituration in 20 mmol/l HEPES, 5
mmol/l KCl, 5 mmol/l MgCl
 
2
 
, 0.5% (v/v) Triton X-100, and
Complete protease inhibitor (Roche Molecular Biochemicals).
Cell debris was removed by centrifugation at 5,000 rpm for 4 min
at 4
 

 
C. The supernatant was collected and stored at 
 

 
70
 

 
C. Pro-
tein concentration was determined by a Lowry assay. Equal
amounts of protein were separated on 7.5% SDS-PAGE gels and
electrophoretically transferred to polyvinylidene difluoride mem-
brane (Millipore) prior to immunodetection with antibodies spe-
cific for the C terminus of ABCA1 (14), anti-glyceraldehyde phos-
phate dehydrogenase (GAPDH, Chemicon) as a loading control,
anti-FLAG (Sigma), or anti-Xpress (Invitrogen), according to the
manufacturers’ recommendations. Immunoreactivity was detected
by enhanced chemiluminescence (Amersham). Protein abundance
was calculated by densitometry using National Institutes of
Health Image 6.0 software and normalized to GAPDH levels.
Densitometry was performed on duplicate or triplicate gels run
from at least three independent experiments, and a wild-type
control was included in each gel.
 
TD4 SNP analysis and Southern blotting
 
Genomic sequencing of the ABCA1 locus, including all exons,
splice junctions, and promoter region was performed as previ-
ously described (1). Southern blot analysis of TD4 genomic DNA
was performed as described (1), using DNA restricted with
 
Bam
 
HI, 
 
Hind
 
III, or 
 
Eco
 
RI and detection with either a probe en-
coding the entire human ABCA1 cDNA or corresponding to the
promoter region of ABCA1 from 
 

 
716 to intron 1.
 
RNA isolation
 
Cytoplasmic RNA was extracted by lysing cell pellets in 10 mM
Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM ethylenediaminetetraace-
tic acid (EDTA), 1% NP40 followed by centrifugation for 30 s.
The supernatant was mixed with an equal volume of 200 mM
Tris, pH 7.5, 350 mM NaCl, 2% SDS, 25 mM EDTA, extracted
twice with phenol-chloroform, once with chloroform, and pre-
cipitated with 1 ml ethanol. Pellets were resuspended in 10 mM
Tris-HCl, pH 7.5, 1 mM MgCl
 
2
 
, 0.1U RNase-free DNaseI (Roche
Molecular Biochemicals), incubated for 30 min, phenol ex-
tracted, and precipitated with ethanol. Pellets were resuspended
in RNase-free water and quantitated by absorbance spectropho-
tometry.
 
Northern blotting
 
Equal amounts (20 
 

 
g) of cytoplasmic RNA were electro-
phoresed through 1% agarose, 2 M formaldehyde gels in MOPS
buffer, and then transferred to Hybond N
 

 
 membrane (Amer-
sham). Membranes were prehybridized and hybridized in a
buffer containing 50% formamide, 10% dextran sulfate (w/v),
0.2% BSA, 0.2% Ficoll, 50 mM Tris HCl, pH 7.5, 0.1% sodium py-
rophosphate, 1% SDS, 0.5% polyvinylpyrrolidone, 1M NaCl, and
0.1 mg/ml denatured salmon sperm DNA. Murine ABCA1 was
detected using a 605 bp fragment of spanning nt positions 1–605
of the murine ABCA1 sequence (Genbank accession X75926).
Probe was randomly labeled with [
 

 
-
 
32
 
P]dCTP using Rediprime
(Amersham) and incubated with the membrane overnight at
42
 

 
C. Membranes were washed sequentially in 2
 

 
 SSC at 42
 

 
C,
and 2
 

 
 SSC, 1% SDS at 60
 

 
C prior to exposure of film.
 
Quantitative PCR
 
Human ABCA1 primers (forward 5
 

 
 CCTGACCGGGTTGT-
TCCC 3
 

 
 and reverse 5
 

 
 TTCTGCCGGATGGTGCTC 3
 

 
 and the
TaqMan probe (5
 

 
ACATCCTGGGAAAAGACATTCGCTCTGA
3
 

 
) were designed using Primer Express software (Applied Bio-
systems, Foster City, CA). RT-PCR reactions were performed on
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an ABI P
 
RISM
 
 7700 machine in a final volume of 50 
 

 
l, containing
40 ng of total RNA, 200 
 

 
M human ABCA1 primers, and 600 
 

 
M
probe in 1
 

 
 TaqMan One-Step RT-PCR Master mix (PE Biosys-
tems, CA), according to the manufacturer’s instructions. Riboso-
mal 18s rRNA primers and probe mix (PE Biosystems) were in-
cluded in the reaction as an internal control. RT reactions were
run at 48
 

 
C for 30 min and heat inactivated at 95
 

 
C for 10 min.
PCR reactions were carried out for 30 cycles (denaturation at
95
 

 
C for 15 s, annealing and extention at 60
 

 
C for 1 min). Data
quantification and analysis were performed according to the
manufacturer’s protocol (PE Biosystems). Values were calculated
relative to the level of the control. Each sample was assayed in
duplicate in at least two independent experiments.
For semiquantitative analysis of RNA extracted from trans-
fected Cos-7 cells, RT-PCR reactions using murine-specific or hu-
man-specific ABCA1 and 18 S ribosomal primers were per-
formed as previously described (14).
 
Cholesterol efflux
 
Lipid levels in TD and FHA patients were measured as de-
scribed and HDL-C was expressed as mmol/l (1, 4). Cellular cho-
lesterol efflux assays on primary human fibroblasts were per-
formed as described (1, 4, 6). Briefly, efflux in the absence or
presence of either 20 or 30 
 

 
g/ml apoA-I was measured over 24 h
and calculated as the percent of free cholesterol in the medium
relative to total cholesterol. Each experiment was performed in
triplicate, averaged, and expressed as the percentage of efflux
relative to the average efflux values obtained from primary fibro-
blasts of two healthy controls included as standards within the same
experiment. Transfected Cos-7 cells were labeled with 1.0 
 

 
Ci/ml
 
3
 
H-cholesterol on the day after transfection. After labeling for
18 h, the cells were washed three times with PBS and incubated
for 2 h with DMEM plus 0.2% defatted BSA (Sigma). The media
was then replaced with fresh DMEM and 0.2% BSA with or with-
out 15 
 

 
g/ml apoA-I for 4 h. Radioactivity in the media was
counted directly, cells were dissolved with 0.1 N NaOH and
counted, and percent efflux was calculated as above. Each exper-
iment was performed at least in triplicate.
 
Statistical analysis
 
Demographics, HDL-C, and apoA-I levels in truncation versus
nontruncation heterzygotes were compared using a two-tailed
Student’s 
 
t
 
-test. Analysis of the proportion of individuals within
given HDL-C percentile ranges was performed by 
 
	
 
2
 
 analysis.
Comparisons of ABCA1 mRNA and protein expression were per-
formed using two-tailed unpaired Student’s 
 
t
 
-tests or, where ap-
plicable, one-way ANOVA with a Neuman-Keuls posttest. All sta-
tistical analyses were performed using Prism (version 3.0;
Graphpad Software for Science Inc., San Diego, CA) or Systat
(version 8.0, SPSS Inc, Chicago, IL).
 
RESULTS
 
HDL-C and apoA-I levels are significantly reduced in
heterozygous carriers of mutations resulting in truncated 
compared with nontruncated ABCA1 alleles
 
We previously examined the phenotypes of 77 heterozy-
gous individuals from 11 FHA and TD families that repre-
sent 13 different ABCA1 mutations and identified an ap-
proximately 40–50% decrease in HDL-C and apoA-I in
heterozygotes compared with unaffected family members
(6). In the present analysis, we excluded two individuals
presumed to be heterozygous based on phenotype and co-
segregation analyses because no mutation within the ABCA1
open reading frame has yet been identified. We also ob-
tained one additional confirmed heterozygous individual
( JP2) (13). The cohort analyzed in this study therefore
consisted of 76 confirmed heterozygous individuals.
To determine the significance of mutation type on
HDL-C and apoA-I levels, heterozygous individuals from
these families were divided into two groups. One group
consisted of all individuals with any mutation predicted to
result in premature truncation of ABCA1, including non-
sense, frameshift, and splice-site mutations. The other
group consisted of individuals with missense or small in-
frame deletions that would result in maintenance of a full-
length allele and specific preservation of the C-terminal
end of ABCA1. This division differed from a previous
analysis (6) by separating the groups on the basis of pre-
dicted protein length (truncation vs. nontruncation)
rather than on that of presumed severity (missense vs.
truncation as well as in-frame deletions).
Comparison of the overall demographics between the
truncation and nontruncation groups showed no differ-
ences in age, body mass index (BMI), or gender distribu-
tions (
 
Fig. 1A
 
). In contrast, apoA-I and HDL-C levels were
Fig. 1. Effect of ABCA1 mutation type on HDL cholesterol (HDL-C)
and apolipoprotein A-I (apoA-I) levels in a cohort of 76 confirmed
heterozygous individuals from 12 different hypoalphalipoprotein-
emia (FHA) and Tangier Disease (TD) families representing trunca-
tion (white bar) and nontruncation (black bar) heterozygotes. A:
Age, body mass index (BMI), and sex are not significantly different
between heterozygous carriers of truncation compared with non-
truncation mutations. The truncation group contained 26 individu-
als, for whom BMI (kg/m2) data were available for 20 persons. Ten
of 26 persons were male in the truncation group. Similarly, the non-
truncation group consisted of 50 individuals for whom BMI data
were present for 40 persons, and 22/50 individuals were male. Com-
parison was done by Student’s t-test. B: HDL-C (mmol/l) and apoA-I
(g/l) levels are reduced in heterozygotes of truncation compared
with nontruncation mutations. The HDL-C and apoA-I values from
heterozygotes for truncation or nontruncation ABCA1 mutations were
averaged and compared using a Student’s t-test. C and D: HDL-C
distributions by absolute level (C) and by age- and sex-normalized
percentile (D) analyzed by 	2 analysis.
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significantly reduced in heterozygotes for truncation mu-
tations compared with nontruncation mutations (
 
P 
 


 
 
 
0.03
and 0.04, respectively) (Fig. 1B). Comparison of the distri-
bution of HDL-C levels between the groups showed that
HDL-C levels are shifted toward lower levels in truncation
compared with nontruncation heterozygotes (Fig. 1C, D).
Significantly, not a single heterozygote for a truncation
mutation had an HDL-C level greater than 1.0 mmol/l,
whereas these levels were observed in approximately 20%
of nontruncation mutation heterozygotes (
 
P 
 


 
 
 
0.01) (Fig.
1C). Finally, significantly more truncation heterozygotes
had HDL-C levels below the 5th percentile for age and sex
than nontruncation heterozygotes (Fig. 1D,
 
 P 
 


 
 0.02).
These results provide the first indication that the type of
mutation in ABCA1 has a significant effect on HDL-C lev-
els in vivo and that truncation mutations depress HDL-C
levels significantly more than nontruncation mutations.
 
Dynamics of ABCA1 expression upon 9-
 
cis
 
-RA,
22-
 
R
 
-OH-Chol treatment
We then sought to determine the mechanism underly-
ing the effect of mutation type on HDL-C levels using
a collection of primary human fibroblasts representing
eight different mutations in ABCA1. Because cAMP does
not induce ABCA1 expression in fibroblasts (15), we be-
gan by characterizing the dynamics of ABCA1 expression
in primary human fibroblasts obtained from healthy con-
trols and RAW macrophages after treatment with 9-cis-RA,
22-R-OH-Chol (8). In primary human fibroblasts, ABCA1
mRNA expression peaks 8 h after stimulation with 9-cis-
RA, 22-R-OH-Chol and diminishes slowly to baseline levels
by 24 h (Fig. 2A, C). ABCA1 protein levels rise rapidly
between 4 and 8 h, peak at 16 h, and are slightly lower at
24 h than at 16 h in fibroblasts (Fig. 2B, C). In RAW cells,
ABCA1 mRNA peaked 4 h after stimulation, whereas pro-
tein levels were maximal by 8 h and both mRNA and pro-
tein levels declined to near baseline levels by 24 h (Fig. 2D).
Truncated ABCA1 dominantly suppresses protein
expression of wild-type ABCA1 in human fibroblasts
Having determined appropriate conditions for detect-
ing ABCA1 protein in primary fibroblasts, the effect of
ABCA1 mutations was evaluated by Western blot analysis
of protein extracted from primary, nontransformed hu-
man fibroblasts from eight FHA and TD families that were
specifically selected to represent a variety of ABCA1 muta-
tions distributed throughout the ABCA1 coding region.
The fibroblasts examined contained several types of muta-
tion, including missense, in-frame deletion of one or
more amino acids, frameshift, and nonsense mutations
(Table 1). Several of the mutations, including a missense
splice site mutation, frameshift, and nonsense mutations,
would be predicted to result in premature termination of
translation of the mutated ABCA1 allele, resulting in the
generation of a truncated ABCA1 fragment. Because both
antibodies used in this study recognize the C terminus of
ABCA1, Western blot analysis of the human fibroblasts
Fig. 2. Dynamics of ABCA1 expression in primary human fibroblasts and RAW murine macrophages in re-
sponse to 9-cis-retinoic acid (9-cis-RA), 22-R-hydroxycholesterol (22-R-OH-Chol) stimulation. A: Northern
blot showing induction of ABCA1 mRNA from 4 to16 h after stimulation. B: Western blot showing stimulated
normal human fibroblasts contain abundant ABCA1 protein from 8 to 24 h after stimulation. C: Densitomet-
ric quantitation of expression dynamics in human fibroblasts. ABCA1 mRNA levels were expressed relative to
rRNA levels, and ABCA1 protein levels were normalized to glyceraldehyde phosphate dehydrogenase
(GAPDH) expression. Data are representative of two independent experiments. D: Densitometric quantita-
tion of induction kinetics of murine ABCA1 mRNA and protein showing maximal mRNA expression at 4 h
and maximal protein expression 8 h after stimulation.
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containing truncation mutations would only detect the
response of the remaining full-length allele to 9-cis-RA, 22-
R-OH-Chol stimulation. In the case of heterozygous FHA
fibroblasts, the remaining allele is wild-type and is pre-
dicted to be functional (Table 1). Cells from the TD
probands are compound heterozygotes and contain one
truncation and one nontruncation mutation (Table 1).
The pattern of ABCA1 protein expression in response
to a 16 h treatment with 9-cis-RA, 22-R-OH-Chol fell into
two groups. In one group, the abundance of ABCA1 pro-
tein in all fibroblasts with missense or small in-frame dele-
tions was approximately 70% that observed in wild-type fi-
broblasts after 16 h of stimulation (Fig. 3A, B, Table 1). A
second pattern was observed in FHA or TD fibroblasts
that contained one truncated allele. In these cells, the
abundance of the remaining full-length ABCA1 allele in
response to 9-cis-RA, 22-R-OH-Chol treatment was mark-
edly reduced (Fig. 3, Table 1). Densitometric quantitation
of ABCA1 protein levels demonstrated that in carriers of
one truncated allele, the remaining full-length allele was
induced only approximately 1.2- to 2.5-fold by 9-cis-RA, 22-
R-OH-Chol, compared with the 10-fold mean induction
observed from pooled data from three different wild-type
control fibroblasts (Fig. 3A, B, Table 1). Importantly, dom-
inant suppression was observed in all cases with a trunca-
tion mutation regardless of whether the second allele was
wild type (in FHA fibroblasts) or contained an additional
mutation (in TD proband fibroblasts). Additionally, equiv-
alent suppression of protein expression was observed re-
gardless of whether protein was harvested at 16 or 24 h af-
ter stimulation (data not shown). These findings suggest
that truncation mutations act to suppress or prevent ex-
pression of full-length ABCA1 protein by a dominant neg-
ative mechanism.
Because the TD fibroblasts contain two mutations, we
next tested whether the decrease in protein abundance in
these compound heterozygous cells was due to the mis-
sense rather than the truncation mutation. ABCA1 pro-
tein levels in heterozygous fibroblasts from the TD1 and
TD3 kindreds that contained only the missense mutations
were comparable to a wild-type control and were clearly
more abundant than in the TD1 or TD3 compound hetero-
zygous cells (Fig. 3C). Densitometic quantitation showed
that the missense mutation alone resulted in a decrease of
no more than 30% in fold induction of ABCA1 protein
upon stimulation with 9-cis-RA, 22-R-OH-Chol, whereas
the additional presence of a truncation mutation further
decreased ABCA1 protein abundance by approximately
65% compared with wild-type control (Fig. 3D). Addition-
ally, efflux assays on these primary fibroblasts demon-
strated that the missense mutation alone slightly dimin-
ished apoA1-dependent cholesterol efflux compared with
wild-type controls, whereas the combination of a missense
plus a truncation mutation further decreased efflux activ-
ity nearly to baseline levels (Fig. 3E). These data confirm
that truncation rather than missense mutations in ABCA1
dominantly suppress expression and functional activity of
ABCA1.
As a negative control, we included TD4 fibroblasts,
which are homozygous for a deletion of C6825 that would
result in truncation of both ABCA1 gene products. Ho-
mozygosity in TD4 cells is supported by complete sequenc-
ing of the ABCA1 gene, a cSNP analysis that demonstrated
homozygosity across the ABCA1 gene except at the ex-
treme 5 end, and Southern blot analysis demonstrating
equivalent bands detected in both TD4 and wild-type con-
trol lanes (data not shown). Even in stimulated TD4 fibro-
blasts, ABCA1 protein is undetectable by either C-terminal
antibody, which confirms the specificity of these antibod-
ies to ABCA1 without detectable cross-reactivity to other
ABC transporters.
Suppression of ABCA1 protein induction by 9-cis-RA,
22-R-OH-Chol occurs at the protein level in fibroblasts 
containing one truncated allele
The failure to observe upregulation of wild-type ABCA1
protein by 9-cis-RA, 22-R-OH-Chol in fibroblasts contain-
ing one truncated allele could occur at the mRNA or pro-
tein levels. To distinguish between these possibilities, cyto-
plasmic RNA was collected from fibroblasts before and
after an 8 h treatment with 9-cis-RA, 22-R-OH-Chol and
quantitatively analyzed for ABCA1 expression using real-
TABLE 1. Expression data by mutation
Family Mutation Proteinc Induced/Uninduced HDL-C Net Effluxd
mmol/l % of control
FHA1 Del L 693 5.95 (0.82) 0.4 79.47 (22.63)
FHA2 R2144X 2.45 (0.19) 0.18 64.01 (11.12)
FHA3 Del E,D 1893, 1894 7.82 (1.48) 0.39 60.03 (11.85)
FHA4 R909X 2.32 (0.52) 0.18 72.28 (18.01)
FHA5 M1091T 6.42 (0.29) 0.1 47.24 (3.79)
TD1 ivs2511G-C, C1477R 3.46 (0.50) 0.1 2.73 (1.05)
TD1-ha C1477R 10.28 (1.07) 0.9 58.14 (5.49)
TD3 GG 5277C - 1636 2.89 (0.59) 0.09 23.3 (1.29)
TD3-hb T9291 6.65 (0.10) 1.12 51.8 (1.30)
TD4 Del C 6825 - 2145X, unidentified 1.14 (0.13) 0.03 17.22 (0)
Control None 11.31 (0.68) 1.63 100.00 (7.09)
a TD1-h is the heterozygous parent of the TD1 proband.
b TD3-h is the heterozygous parent of the TD3 proband.
c Protein values are pooled from all determinations (n 
 3–7) and are represented as mean (standard error).
d Efflux values are pooled from at least three determinations expressed as % mean (standard deviation) relative to control fibroblasts from the
same experiment.
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time RT-PCR analysis using the Light Cycler (Roche). The
8 h time point was selected because it coincided with the
midpoint of mRNA expression as determined by North-
ern blot analysis of wild-type fibroblasts. Real-time PCR
quantitation showed that ABCA1 mRNA was present in
each fibroblast type 8 h after stimulation (Fig. 4A). Al-
though there are differences in the level of ABCA1 mRNA
detected among fibroblasts from different genetic back-
grounds, there were no significant differences between
the truncation compared with nontruncation samples (N 

5–8, P  0.05), confirming that ABCA1 mRNA is upregu-
lated in response to 9-cis-RA, 22-R-OH-Chol in all cell
types. Additionally, we determined the ratio of fold induc-
tion of ABCA1 protein relative to the fold induction of
ABCA1 mRNA (Fig. 4B). Furthermore, wild-type cells and
the nontruncation mutations were found to generate sim-
ilar levels of ABCA1 protein per mRNA (Fig. 4B, P 
0.05), whereas all of the fibroblasts containing truncation
mutations were impaired in their ability to generate
ABCA1 protein (Fig. 4B, P  0.0001). Additionally, the in-
duction of ABCA1 mRNA is not significantly different be-
tween truncation and nontruncation fibroblasts (P 
0.05). Therefore, the failure to observe ABCA1 protein
upregulation in cells containing truncation mutations is
most likely due either to decreased translational efficiency
of the full-length allele or increased turnover of the full-
length protein in the presence of the truncated protein
product.
Dominant negative suppression of ABCA1 activity in vitro
Data presented above support the hypothesis that trun-
cation mutations in one ABCA1 allele dominantly sup-
press protein induction of the remaining full-length al-
lele. To test this hypothesis further, we evaluated the effect
of truncation versus missense mutations on ABCA1 ex-
pression and cholesterol efflux activity using Cos-7 cells
cotransfected with wild-type and truncated or nontrun-
cated human ABCA1 cDNA constructs.
Cells transfected with Xpress-tagged wild-type ABCA1
alone expressed ABCA1 protein and exhibited apoA-I-
dependent cholesterol efflux compared with vector only
(mock) transfected cells (P  0.001, n 
 3, Fig. 5A, B).
Cotransfection of FLAG-tagged wild-type and Xpress-
tagged wild-type ABCA1 resulted in a doubling of efflux
activity (P  0.001, n 
 3), and Western blotting showed
that wild-type ABCA1 protein was expressed from both
Fig. 3. ABCA1 protein expression in response to 9-cis-RA, 22-R-OH-Chol stimulation. A: RAW murine macrophages, wild-type human pri-
mary fibroblasts, and primary fibroblasts from eight TD or FHA families were harvested after a 16 h exposure to delipidated serum growth
media without () and with () 10 M each of 9-cis-RA, 22-R-OH-Chol. ABCA1 protein is markedly reduced in stimulated cells with trunca-
tion mutations compared with nontruncation mutations. Equivalent results were obtained using two different verified ABCA1 antibodies. B:
Densitometric quantitation of ABCA1-GAPDH protein upregulation in stimulated fibroblasts, demonstrating reduced ABCA1 levels in stim-
ulated fibroblasts with truncation mutations compared with nontruncation mutations. Values represent the mean of 3 to 5 independent ex-
periments for each fibroblast cell type. Three different wild-type fibroblasts, each assayed in triplicate, were pooled to give an overall induc-
tion in wild-type fibroblasts. Statistical comparison is by one-way ANOVA with a Neuman-Kuels posttest. C: Western blot of ABCA1 protein in
wild-type, TD1, and TD3 compound heterozygote, and TD1-h and TD3-h heterozygous fibroblasts stimulated as above. D: Densitometric
quantitation of triplicate experiments from C, in which one wild-type fibroblast was used as a control. Data from the quantitations in B and
D were pooled to give the values represented in Table 1. E: Cholesterol efflux activity over 24 h in wild-type, TD1, and TD3 compound het-
erozygote, and TD1-h and TD3-h heterozygous fibroblasts. Data represent the mean of triplicate measurements performed side by side with
two wild-type controls (pooled) in the absence () or presence () of 20 g/ml apoA-I.
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constructs (Fig. 5A, B). It should be noted that because
the Xpress and FLAG antibodies have different affinities,
Western blotting cannot be used to estimate the relative
levels of ABCA1 expressed from either tagged construct.
Next, cells were cotransfected with Xpress-tagged wild-
type and FLAG-tagged mutant ABCA1. By Western blot,
expression of the FLAG-tagged truncated construct is de-
tectable but low, suggesting that truncation of ABCA1 may
destabilize the protein (Fig. 5A). Additionally, abundance
of the wild-type Xpress-tagged construct was reduced
when coexpressed with truncated ABCA1. Coexpression
of FLAG-tagged ABCA1 truncated at amino acid 1851
(R1851X) significantly inhibited efflux compared with
cells transfected with a single copy of wild-type ABCA1 (P 
0.001, n 
 3, Fig. 5B). Finally, cells were cotransfected
with Xpress-tagged wild-type and FLAG-tagged missense
ABCA1 (N1611D). Western blot analysis confirmed that
both alleles expressed protein and that the presence of
ABCA1 containing a missense mutation did not decrease
the abundance of wild-type ABCA1 (Fig. 5A). As expected,
efflux was comparable to cells singly transfected with wild-
type ABCA1 (Fig. 5B, P  0.05, n 
 3). These data con-
firm that truncated ABCA1 interferes with the stable ex-
pression and functional activity of wild-type ABCA1.
To rule out the possibility that differences in mRNA ex-
pression between the FLAG-tagged wild-type, truncation,
and missense constructs were responsible for the observed
differences in protein level and efflux activity, semiquanti-
tative RT-PCR analysis was performed on transfected cells.
The results show that each of the FLAG-tagged constructs
is similarly expressed in transfected cells (Fig. 5C), con-
firming that the dominant negative inhibition of ABCA1
protein levels and efflux activity occurs at a posttranscrip-
tional level.
ABCA1 protein levels predict HDL-C levels
The clinical spectrum of TD and FHA patients results
from defective ABCA1-mediated efflux of cholesterol
and/or phospholipid, which in turn is a function of
ABCA1 level and catalytic activity. Increasing ABCA1 pro-
tein levels in mice has recently been shown to increase
HDL-C levels in vivo in two of three animal models (16–
18). Because the sample size of fibroblasts is small, it is dif-
ficult to draw strong conclusions about the effect of
ABCA1 protein level and HDL-C levels in vivo. Neverthe-
less, we did observe that protein induction and HDL-C
correlated strongly (Fig. 6A, r2 
 0.67, P 
 0.002), sug-
gesting that the degree of ABCA1 protein expression in
primary fibroblasts predicted HDL-C levels in vivo. ABCA1
protein levels and cholesterol efflux activity in fibroblasts
was also correlated and nearly reached statistical signifi-
cance (Fig. 6B, r2 
 0.33, P 
 0.06). Strikingly, for both
correlations, all of the fibroblasts expressing ABCA1 with
truncation mutations clustered near the bottom of the
curve, whereas all of the fibroblasts expressing nontrunca-
tion ABCA1 mutations clustered at an intermediate posi-
tion between wild-type and truncation mutation cells.
DISCUSSION
ABCA1 has been identified as a key initiator of reverse
cholesterol transport and plays an important role in medi-
ating susceptibility to atherosclerosis (19). Using a large
cohort of affected and unaffected family members that al-
lows us to partly control for other genetic and environ-
mental influences, we recently showed that ABCA1 het-
erozygotes have reduced HDL-C and apoA-I levels that are
gene-dose dependent and demonstrate a critical role for
ABCA1 in determining HDL-C levels (6). In this analysis,
the effect of mutation type was assessed by comparing the
HDL-C levels in carriers of missense versus frameshift,
nonsense, and small in-frame deletions, and no significant
effect was found (6). However, when separated by the ef-
Fig. 4. ABCA1 mRNA expression in response to 9-cis-RA, 22-
R-OH-Chol stimulation in human fibroblasts. Cytoplasmic RNA was
collected from unstimulated cells as well as cells stimulated for 8 h
and subjected to quantitative determination of ABCA1 mRNA us-
ing the Light-Cycler. A: Data from two independent experiments,
each performed in triplicate, are pooled. Levels of ABCA1 mRNA
in stimulated cells vary among individual fibroblasts, but are not
consistently lower in truncation versus nontruncation samples. Sta-
tistical comparison is by one-way ANOVA with a Neuman-Keuls
posttest. B: Relative protein per RNA was calculated by determining
the ratio of fold induction of ABCA1 protein (normalized to
GAPDH) relative to fold induction of ABCA1 mRNA (normalized
to 18s rRNA) in stimulated compared with unstimulated fibro-
blasts. Values represent means from two independent experiments,
with each measurement performed in triplicate. Statistical compar-
ison is by one-way ANOVA with a Neuman-Keuls posttest.
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fect of the mutation on protein length, heterozygotes for
truncation mutations were found to have significantly
lower HDL-C and apoA-I levels than heterozygotes for
nontruncation mutations, suggesting that truncation mu-
tations have a deleterious effect in vivo.
We now provide a molecular mechanism that may help
to explain the clinical variation of individual phenotypes
in FHA and TD kindreds through the analysis of ABCA1
expression in primary human fibroblasts representative of
a variety of mutation types located throughout the ABCA1
protein coding region. We observed a profound effect of
mutation type on the ability of ABCA1 protein to be up-
regulated in response to oxysterol stimulation. Premature
truncations of ABCA1 were found to dominantly inhibit
expression of the remaining full-length allele, regardless
of whether the full-length allele was wild type or whether
it contained a second, nontruncation mutation. In con-
trast, mutations that maintained ABCA1 translation to its
natural C terminus resulted in protein levels that were ap-
proximately 70% of those observed in wild-type cells. Fur-
thermore, suppression of ABCA1 expression by trunca-
tion mutations occurred at the protein level because
ABCA1 mRNA levels are comparable in these fibroblasts.
Therefore, a reduction in the steady-state level of ABCA1
protein must be due either to decreased translation or to
increased degradation of ABCA1 protein. These findings
Fig. 5. Dominant negative suppression of ABCA1 activity in transfected cells. Cos-7 cells were transfected
singly with vector (mock), Xpress-tagged wild-type human ABCA1 cDNA (WT/Xpress), or cotransfected
with FLAG-tagged wild-type ABCA1 (WT/Xpress  WT/FLAG), FLAG-tagged ABCA1 containing the
N1611D mutation (WT/Xpress  N1611D/FLAG), or with FLAG-tagged ABCA1 containing the R1851X
mutation (WT/Xpress  R1851X/FLAG). A: Western blot analysis of vector or ABCA1-transfected cells us-
ing the Xpress or FLAG antibodies. The positions of full-length or truncated ABCA1 are marked. B: ApoA-I-
dependent cholesterol efflux activity in vector or ABCA1-transfected cells. Efflux is expressed as the percent
of counts in the medium relative to total counts in cells plus medium. Data are representative of three inde-
pendent experiments. Statistical comparison is by one-way ANOVA with a Neuman-Kuels posttest. C: Semi-
quantitative RT-PCR using human-specific ABCA1 primers as well as 18s rRNA primers as an internal control.
RNA was prepared from untransfected Cos-7 cells or cells singly transfected with FLAG-tagged ABCA1 con-
structs.
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may explain why FHA or TD heterozygotes for truncation
mutations are doubly disadvantaged; not only is one allele
nonfunctional by virtue of a severe mutation, but in addi-
tion, expression of the remaining wild-type allele is also
compromised.
Furthermore, our results suggest that ABCA1 protein
levels strongly predict HDL-C and cholesterol efflux. Im-
portantly, we observed that truncation and nontruncation
mutations formed nonoverlapping clusters in correlation
analyses between ABCA1 protein levels and either HDL-C
or cholesterol efflux. For both correlations, all of the trun-
cation mutations clustered near the bottom of these
curves, consistent with dominant negative suppression of
ABCA1 expression and activity by truncation mutations.
These results confirm that truncation mutations are the
most severe with respect to their effects on HDL-C levels,
cholesterol efflux, and ABCA1 protein levels. In contrast,
all of the nontruncation mutations clustered in an inter-
mediate region of the curve, suggesting that nontruncation
mutations do not generally have a dominant negative effect
on expression of function of the remaining ABCA1 allele.
The dominant negative effect of ABCA1 truncation mu-
tations was also confirmed in a synthetic in vitro system us-
ing Cos-7 cells transfected with tagged cDNA expression
constructs encoding wild-type or truncated ABCA1. Coex-
pression of wild-type ABCA1 with ABCA1 containing a
missense mutation did not inhibit expression or efflux ac-
tivity of wild-type ABCA1. By contrast, coexpression of
wild-type with truncated ABCA1 decreased cholesterol ef-
flux from wild-type ABCA1 by approximately 65%, dem-
onstrating that ABCA1 fragments dominantly interfere
with ABCA1 functional activity.
Dominant negative effects are classically defined in
terms of function and can manifest in several ways. Some
dominant negative mutations inactivate catalytic activity
while maintaining the ability to bind substrate (20–22).
Fig. 6. ABCA1 protein levels correlate with plasma HDL-C levels and efflux activity. A: The fold increase in
ABCA1-GAPDH levels observed upon stimulation of primary fibroblasts with 9-cis-RA, 22-R-OH-Chol (x axis)
are plotted against the HDL-C levels from the patient from whom the fibroblasts were obtained (y axis),
showing a strong, significant positive correlation (r2 
 0.68, P 
 0.002). Black square, wild-type; gray circle,
nontruncation mutation; open triangle, truncation mutation. B: The fold increase in ABCA1:GAPDH levels
(x axis) are plotted against the cholesterol efflux activity from the patient from whom the fibroblasts were ob-
tained (y axis), showing a positive correlation that nearly reaches statistical significance (r2 
 0.33, P 
 0.06).
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Other common dominant negative mutations include
truncated molecules that maintain ligand- or target-bind-
ing functions but lack other functional domains (23–26).
Dominant negative mutations work by inhibiting the func-
tion of the wild-type allele, which often occurs by the mu-
tated allele “poisoning” a molecular complex or titrating
key components required for function. For example,
many fibrillin-1 gene mutations generate fibrillin mono-
mers that impair the global function of microfibrils and
result in microfibrillopathies, including Marfan syndrome
(27). Additionally, a truncation mutation in endoglin re-
sults in a protein fragment that dimerizes with wild-type
endoglin protein and dominantly impairs its trafficking to
the cell surface (28). Similarly, truncated V2 vasopressin
receptors act as dominant negative regulators of wild-type
V2 receptor function by inhibiting function and cell sur-
face trafficking of full-length V2 receptors (29).
The finding that truncation mutations in ABCA1 can
dominantly suppress protein expression of full-length
ABCA1 suggests that association of ABCA1 molecules with
other proteins may be required for maintenance of normal
ABCA1 protein levels in cells. It is possible that ABCA1 may
form higher order complexes that may be critical for its sta-
ble accumulation or expression at the cell surface. ABCA1
is a full-size ATP-binding cassette transporter and as such
contains all domains required for transporter function in a
single molecule (30). Quarter-sized and half-size transport-
ers necessarily form functional complexes for activity (31–
34). What is less clear is whether full-sized ATP-binding cas-
sette transporters also have the ability to form functional
dimers or other higher order complexes. Our results sug-
gest that higher order complexes may be necessary for
maintenance of protein abundance and functional activity
at the cell surface because coexpression of one truncated
allele is sufficient to significantly reduce overall protein lev-
els and diminish efflux activity.
Much current research aims to identify compounds that
increase ABCA1 levels in cells. However, if these com-
pounds act to increase ABCA1 expression through tran-
scriptional mechanisms, we would predict that they would
be less effective in patients with truncation mutations, be-
cause expression of ABCA1 would remain impaired by the
effect of the truncation mutation on ABCA1 translation or
protein stability. Conversely, compounds that act at post-
transcriptional levels to enhance ABCA1 expression or
that enhance ABCA1 activity, perhaps through modulat-
ing the interactions of ABCA1 with its protein partners,
may be more desirable as potential therapeutics for these
patients.
The authors thank Joan Keiser, Ming Wang, Omar Francone,
Mark Gray-Keller, Alan Attie, Shizuya Yamashita, Yuji Matsu-
zawa, and members of our respective groups for their generous
contributions. This work is supported by the Canadian Insti-
tutes of Health Research (S.M.C., J.G., and M.R.H.), the Heart
and Stroke Foundation of Canada (M.R.H.), the Canadian Net-
works of Centres of Excellence (NCE Genetics, M.R.H.), and
Xenon Genetics Inc. (Y-Z.Y., S.Z., S.N., K.R., J.C., A.B., M.R.H.).
K.Z. is supported by a grant from the Netherlands Heart Foun-
dation. J.G. is supported by a Chercheur National salary award
from the Fonds de la recherche en sante de Quebec. J.J.P.K. is
an Established Investigator of the Dutch Heart Foundation.
M.R.H. is a holder of a Canada Research Chair.
REFERENCES
1. Brooks-Wilson, A., M. Marcil, S. M. Clee, L. Zhang, K. Roomp, M.
van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. F. Molhuizen, O.
Loubser, B. F. F. Ouellette, K. Fichter, K. J. D. Ashbourne Excoffon,
C. W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J.
Frohlich, K. Morgan, B. Koop, S. N. Pimstone, J. J. P. Kastelein, J.
Genest, Jr., and M. R. Hayden. 1999. Mutations in ABCA1 in Tan-
gier disease and familial high-density lipoprotein deficiency. Nat.
Genet. 22: 336–345.
2. Bodzioch, M., E. Orsó, J. Klucken, T. Langmann, A. Böttcher, W.
Diederich, W. Drobnik, S. Barlage, C. Büchler, M. Porsch-
Özcürümez, W. E. Kaminski, H. W. Hahmann, K. Oette, G. Rothe,
C. Aslanidis, K. J. Lackner, and G. Schmitz. 1999. The gene encod-
ing ATP-binding cassette transporter 1 is mutated in Tangier Dis-
ease. Nat. Genet. 22: 347–351.
3. Rust, S., M. Rosier, H. Funke, Z. Amoura, J-C. Piette, J-F. Deleuze,
H. B. Brewer, Jr., N. Duverger, P. Denèfle, and G. Assmann. 1999.
Tangier Disease is caused by mutations in the gene encoding ATP-
binding cassette transporter 1. Nat. Genet. 22: 352–355.
4. Marcil, M., A. Brooks-Wilson, S. M. Clee, K. Roomp, L. Zhang, L.
Yu, J. A. Collins, M. van Dam, H. O. F. Molhuizen, O. Loubser, B. F. F.
Ouellette, C. W. Sensen, K. Fichter, S. Mott, M. Denis, B. Boucher,
S. Pimstone, J. Genest, Jr., J. J. P. Kastelein, and M. R. Hayden.
1999. Mutations in the ABCA1 gene in familial HDL deficiency
with defective cholesterol efflux. Lancet. 354: 1341–1346.
5. Fredrickson, D. S., P. H. Altrocchi, L. V. Avioli, D. W. S. Goodman,
and H. C. Goodman. 1961. Tangier Disease. Ann. Intern. Med. 55:
1016–1031.
6. Clee, S. M., J. J. P. Kastelein, M. van Dam, M. Marcil, K. Roomp, K. Y.
Zwarts, J. A. Collins, R. Roelants, N. Tamasawa, T. Stulc, T. Suda, R.
Ceska, B. Boucher, C. Rondeau, C. DeSouich, A. Brooks-Wilson,
H. O. F. Molhuizen, J. Frohlich, J. Genest, Jr., and M. R. Hayden.
2000. HDL cholesterol levels and coronary artery disease in het-
erozygotes for ABCA1 mutations are predicted by cholesterol ef-
flux levels and influenced by age. J. Clin. Invest. 106: 1263–1270.
7. Brousseau, M. E., G. P. Eberhart, J. Dupuis, B. F. Asztalos, A. L.
Goldkamp, E. J. Schaefer, and M. W. Freeman. 2000. Cellular cho-
lesterol efflux in heterozygotes for Tangier disease is markedly re-
duced and correlates with high density lipoprotein cholesterol
concentration and particle size. J. Lipid Res. 41: 1125–1135.
8. Repa, J. J., S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig,
B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf.
2000. Regulation of absorption and ABCA1-mediated efflux of
cholesterol by RXR heterodimers. Science. 289: 1524–1529.
9. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABCA1 gene ex-
pression and ApoA-I-mediated cholesterol efflux are regulated by
LXR. Biochem. Biophys. Res. Commun. 274: 794–802.
10. Costet, P., Y. Luo, N. Wang, and A. R. Tall. 2000. Sterol-dependent
transactivation of the ABCA1 promoter by the liver X receptor/
retinoid X receptor. J. Biol. Chem. 275: 28240–28245.
11. Wang, N., D. L. Silver, P. Costet, and A. R. Tall. 2000. Specific bind-
ing of ApoA-I, enhanced cholesterol efflux, and altered plasma
membrane morphology in cells expressing ABCA1. J. Biol. Chem.
275: 33053–33058.
12. Pullinger, C. R., H. Hakamata, P. N. Duchateau, C. Eng, B. E.
Aouizerat, M. H. Cho, C. J. Fielding, and J. P. Kane. 2000. Analysis
of hABCA1 gene 5 end: additional peptide sequence, promoter
region, and four polymorphisms. Biochem. Biophys. Res. Commun.
271: 451–455.
13. Nishida, Y., K. Hirano, K. Tsukamoto, M. Nagano, C. Ikegami, K.
Roomp, M. Ishihara, N. Sakane, Z. Zhang, K. Tsujii, A. Matsuyama,
T. Ohama, F. Matsuura, M. Ishigami, N. Sakai, H. Hiraoka, H. Hat-
tori, C. Wellington, Y. Yoshida, S. Misugi, M. R. Hayden, T. Ega-
shira, S. Yamashita, and Y. Matsuzawa. 2002. Expression and func-
tional analyses of novel mutations of ATP-binding cassette
transporter-1 in Japanse patients with high-density lipoprotein de-
ficiency. Biochem. Biophys. Res. Commun. 290: 713–721.
 by guest, on M
arch 31, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
Wellington et al. Dominant negative ABCA1 truncation mutations 1949
14. Wellington, C. L., E. K. Walker, A. Suarez, A. Kwok, N. Bissada, R.
Singaraja, Y-Z. Yang, L. H. Zhang, E. James, J. E. Wilson, O. Fran-
cone, B. M. McManus, and M. R. Hayden. 2002. ABCA1 mRNA
and protein distribution patterns predict multiple different roles
and levels of regulation. Lab. Invest. 82: 273–283.
15. Bortnick, A. E., G. H. Rothblat, G. Stoudt, K. L. Hoppe, L. J. Royer,
J. McNeish, and O. L. Francone. 2000. The correlation of ATP-
binding cassette 1 mRNA levels with cholesterol efflux from vari-
ous cell lines. J. Biol. Chem. 275: 28634–28640.
16. Singaraja, R. R., V. Bocher, E. R. James, S. M. Clee, L-H. Zhang,
B. R. Leavitt, B. Tan, A. Brooks-Wilson, A. Kwok, N. Bissada, Y-Z.
Yang, G. Liu, S. R. Tafuri, C. Fievet, C. L. Wellington, B. Staels, and
M. R. Hayden. 2001. Human ABCA1 BAC transgenic mice show in-
creased HDL-C and ApoA-I-dependent efflux stimulated by an in-
ternal promoter containing LXREs in intron 1. J. Biol. Chem. 276:
33969–33979.
17. Vaisman, B. L., G. Lambert, M. Amar, C. Joyce, T. Ito, R. D. Sham-
burek, W. J. Cain, J. Fruchart-Najib, E. D. Neufeld, A. T. Remaley,
H. B. Brewer, Jr., and S. Santamarinao-Fojo. 2001. ABCA1 overex-
pression leads to hyperalphalipoproteinemia and increased biliary
cholesterol excretion in transgenic mice. J. Clin. Invest. 108: 303–
309.
18. Cavelier, L. B., Y. Qiu, J. K. Bielicki, V. Afzal, J-F. Cheng, and E. M.
Rubin. 2001. Regulation and activity of the human ABCA1 gene in
transgenic mice. J. Biol. Chem. 276: 18046–18051.
19. Singaraja, R., C. Fievet, G. Castro, E. R. Jamers, N. Hennuyer, S. M.
Clee, N. Bissada, J. C. Choy, J-C. Fruchart, B. M. McManus, and
M. R. Hayden. 2002. Increased ABCA1 activity protects against ath-
erosclerosis. J. Clin. Invest. 110: 35–42.
20. Zhu, K., B. Debreceni, R. Li, and Y. Zheng. 2000. Identification of
Rho GTPase-dependent sites in the Dbl homology domain of on-
cogenic Dbl that are required for transformation. J. Biol. Chem.
275: 25993–26001.
21. Mukherjee, S., J. E. Casanova, and M. Hunzicker-Dunn. 2001. De-
sensitization of the luteinizing hormone/choriogonadotropin re-
ceptor in ovarian follicular membranes is inhibited by catalytically
inactive ARNO. J. Biol. Chem. 276: 6524–6528.
22. Pitson, S. M., P. A. B. Moretti, J. R. Zebol, P. Xia, J. R. Gamble,
M. A. Vadas, R. J. D’Andrea, and B. W. Wattenberg. 2000. Expres-
sion of a catalytically inactive sphingosine kinase mutant blocks ag-
onist-induced sphingosine kinase activation. A dominant-negative
sphingosine kinase. J. Biol. Chem. 275: 33945–33950.
23. Love, J. D., J. T. Gooch, L. Nagy, V. K. Chatterjee, and J. W.
Schwabe. 2000. Transcriptional repression by nuclear receptors:
mechanisms and roles in disease. Biochem. Soc. Trans. 28: 390–396.
24. Williams, D. A., W. Tao, F. Yang, C. Kim, Y. Gu, P. Mansfield, J. E.
Levine, B. Petryniak, C. W. Derrow, C. Harris, B. Jia, Y. Zheng,
D. R. Ambruso, J. B. Lowe, S. J. Atkinson, M. C. Dinauer, and L.
Boxer. 2000. Dominant negative mutation of the hematopoietic-
specific Rho GTPase, Rac2, is associated with a human phagocyte
immunodeficiency. Blood. 96: 1646–1654.
25. Gosslar, U., R. Shmid, and B. Holzmann. 1999. Regulation of EGR-
1-dependent gene expression by the C-terminal activation do-
main. Biochem. Biophys. Res. Commun. 255: 208–215.
26. Singh, S., H. Tang, J-Y. Lee, and G. Saunders. 1998. Truncation
mutations in the transactivation region of PAX6 result in domi-
nant-negative mutants. J. Biol. Chem. 273: 21531–21541.
27. Robinson, P. N., and M. Godfrey. 2000. The molecular genetics of
Marfan syndrome and related microfibrillopathies. J. Med. Genet.
37: 9–25.
28. Lux, A., C. Gallione, and D. Marchuck. 2000. Expression analysis of
endoglin missense and truncation mutations: insights into protein
structure and disease mechanisms. Hum. Mol. Genet. 9: 745–755.
29. Zhu, X., and J. Wess. 1998. Truncated V2 vasopressin receptors as
negative regulators of wild-type V2 receptor function. Biochemistry.
37: 15773–15784.
30. Klein, I., B. Sarkadi, and A. Váradi. 1999. An inventory of the hu-
man ABC proteins. Biochim. Biophys. Acta. 1461: 237–262.
31. van Veen, H. W., and W. N. Konings. 1998. The ABC family of mul-
tidrug transporters in microorganisms. Biochim. Biophys. Acta.
1365: 31–36.
32. Braibant, M., P. Gilot, and J. Content. 2000. The ATP binding cas-
sette (ABC) transport systems of mycobacterium tuberculosis.
FEMS Microbiol. Rev. 24: 449–467.
33. Saier, M. H., Jr. 2000. Families of transmembrane transporters se-
lective for amino acids and their derivatives. Microbiology. 146:
1775–1795.
34. Jetté, L., M. Potier, and R. Béliveau. 1997. P-Glycoprotein is a
dimer in the kidney and brain capillary membranes: effect of cy-
closporin A and SDZ-PSC 833. Biochemistry. 36: 13929–13937.
 by guest, on M
arch 31, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
